QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 26, no. 1 (2007): 62-74
doi: 10.1377/hlthaff.26.1.62
© 2007 by Project HOPE
 
New Online
 * How Would Obama, McCain Cover The Uninsured?
 * Debating Cost Of Uninsured
 * Try Medicare-For-All
 * HA Blog Top 10
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when eLetters are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in ISI Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via ISI Web of Science (5)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Califf, R. M.
* Articles by Schulman, K. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Califf, R. M.
* Articles by Schulman, K. A.
Related Collections
* Cardiovascular Disease
* Chronic Care
* Consumer Issues
* Health Promotion/Disease Prevention
* Public Health
* Research And Technology

Quality

Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics

Robert M. Califf, Robert A. Harrington, Leanne K. Madre, Eric D. Peterson, Deborah Roth and Kevin A. Schulman

Despite decades of progress in the diagnosis, treatment, and prevention of cardiovascular disease, its prevalence continues to grow in both developed and developing countries. We have constructed a model, the "cycle of quality," which connects the innovation of initial scientific discovery with validated methods of translating research into effective delivery. This model can serve as a basis for evaluating proposed efforts to improve interactions among private and public aspects of health care to accelerate development and appropriate adoption of new treatments, and to achieve greater penetration of effective behavioral therapies and established technologies, resulting in major improvements in cardiovascular health.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
R. Peto, J. Emberson, M. Landray, C. Baigent, R. Collins, R. Clare, and R. Califf
Analyses of Cancer Data from Three Ezetimibe Trials
N. Engl. J. Med., September 2, 2008; (2008) NEJMsa0806603v1.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. Himmelfarb
Chronic Kidney Disease and the Public Health: Gaps in Evidence From Interventional Trials
JAMA, June 20, 2007; 297(23): 2630 - 2633.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R. M. Califf
The cycle of quality as a model for improving health outcomes in the treatment of hypertension
Eur. Heart J. Suppl., May 1, 2007; 9(suppl_B): B8 - B12.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
E. L. Eisenstein, D. F. Kong, K. J. Anstrom, and R. M. Califf
Clopidogrel and Long-term Outcomes After Drug-Eluting Stent Implantation--Reply
JAMA, April 25, 2007; 297(16): 1770 - 1771.
[Full Text] [PDF]


Home page
JAMAHome page
K. W. Mahaffey and R. A. Harrington
Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions
JAMA, February 14, 2007; 297(6): 636 - 639.
[Full Text] [PDF]



Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2007 Project HOPE–The People-to-People Organization
Terms and Policies